CDK6 is altered in 1.01% of malignant solid tumor patients with CDK6 Mutation present in 0.39% of all malignant solid tumor patients [4].

CDK6 Mutation is an inclusion criterion in 6 clinical trials for malignant solid tumor, of which 5 are open and 1 is closed. Of the trials that contain CDK6 Mutation and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 5 are phase 2 (4 open) [5].

CDK6 is altered in 1.24% of medulloblastoma patients [4].

CDK6 Mutation is an inclusion criterion in 6 clinical trials for medulloblastoma, of which 6 are open and 0 are closed. Of the trials that contain CDK6 Mutation and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 4 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain CDK6 Mutation and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [5].

CDK6 is altered in 1.3% of central nervous system embryonal neoplasm patients with CDK6 Mutation present in 0.43% of all central nervous system embryonal neoplasm patients [4].

CDK6 Mutation is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Mutation and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

CDK6 is altered in 0.81% of breast carcinoma patients with CDK6 Mutation present in 0.24% of all breast carcinoma patients [4].

CDK6 Mutation is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain CDK6 Mutation and breast carcinoma as inclusion criteria, 2 are phase 2 (0 open) [5].

CDK6 is altered in 0.72% of non-hodgkin lymphoma patients with CDK6 Mutation present in 0.2% of all non-hodgkin lymphoma patients [4].

CDK6 Mutation is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Mutation and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CDK6 Mutation is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Mutation and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Mutation and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Mutation and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

CDK6 is altered in 6.25% of large cell/anaplastic medulloblastoma patients [4].

CDK6 Mutation is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Mutation and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Mutation and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Mutation and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [5].

CDK6 Mutation is an inclusion criterion in 2 clinical trials for medulloblastoma, WNT-activated, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Mutation and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 Mutation and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [5].

CDK6 is altered in 1.11% of endometrial endometrioid adenocarcinoma patients with CDK6 Mutation present in 1.11% of all endometrial endometrioid adenocarcinoma patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 1.52% of melanoma patients with CDK6 Mutation present in 0.86% of all melanoma patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 1.83% of head and neck squamous cell carcinoma patients with CDK6 Mutation present in 0.77% of all head and neck squamous cell carcinoma patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 1.09% of squamous cell lung carcinoma patients with CDK6 Mutation present in 0.76% of all squamous cell lung carcinoma patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [5].

CDK6 is altered in 0.62% of anaplastic oligodendroglioma patients with CDK6 Mutation present in 0.62% of all anaplastic oligodendroglioma patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 is altered in 0.78% of colorectal carcinoma patients with CDK6 Mutation present in 0.52% of all colorectal carcinoma patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK6 Mutation and colorectal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CDK6 is altered in 2.17% of gastric carcinoma patients with CDK6 Mutation present in 0.38% of all gastric carcinoma patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK6 Mutation and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CDK6 is altered in 0.95% of cancer patients with CDK6 Mutation present in 0.37% of all cancer patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains CDK6 Mutation and cancer as inclusion criteria, 1 is phase 2 (0 open) [5].

CDK6 is altered in 1.38% of diffuse glioma patients with CDK6 Mutation present in 0.37% of all diffuse glioma patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 is altered in 1.62% of glioblastoma patients with CDK6 Mutation present in 0.34% of all glioblastoma patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 is altered in 1.49% of malignant glioma patients with CDK6 Mutation present in 0.31% of all malignant glioma patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 is altered in 0.49% of ovarian carcinoma patients with CDK6 Mutation present in 0.31% of all ovarian carcinoma patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 0.45% of ovarian epithelial tumor patients with CDK6 Mutation present in 0.3% of all ovarian epithelial tumor patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and ovarian epithelial tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 1.43% of anaplastic astrocytoma patients with CDK6 Mutation present in 0.29% of all anaplastic astrocytoma patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 is altered in 4.65% of esophageal carcinoma patients with CDK6 Mutation present in 0.24% of all esophageal carcinoma patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK6 Mutation and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CDK6 is altered in 0.78% of B-cell non-hodgkin lymphoma patients with CDK6 Mutation present in 0.17% of all B-cell non-hodgkin lymphoma patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 0.55% of germ cell tumor patients with CDK6 Mutation present in 0.14% of all germ cell tumor patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDK6 Mutation and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 is altered in 1.75% of anaplastic ependymoma patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 1.09% of high-grade glioma, NOS patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 is altered in 1.29% of mucosal melanoma patients [4].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [5].

CDK6 Mutation is an inclusion criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 Mutation and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].